Chronic Rhinosinusitis

The fluticasone exhalation delivery system is a novel topical steroid delivery system that is an important adjunct therapy for sinonasal inflammatory disease.

The Food and Drug Administration (FDA) has approved Dupixent (dupilumab; Sanofi and Regeneron) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.

There is no significant increased benefit in using a higher-dose nasal steroid spray compared with the standard dose after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis.

Patients with chronic rhinosinusitis with nasal polyps who had a higher concentration of Charcot-Leyden crystals in nasal secretions were more likely to respond to glucocorticoid therapy.

Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pyogenes were found in approximately one-fifth of isolated IgE antibodies via plasmablasts residing in nasal polyps.